menu
    • menu

    Company profile for InCarda Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure o...
    InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InCarda TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    39899 Balentine Drive, Suite 185 Newark, CA 94560
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://incardatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/incarda-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/incardathera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InCarda Therapeutics Announces RESTORE-1 Ph 3 Trial Results
    InCarda Therapeutics Announces RESTORE-1 Ph 3 Trial Results

    30 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240930020909/en

    BUSINESSWIRE
    30 Sep 2024
    Share Share
    InCarda terminates its PhIII trial for arrhythmia drug
    InCarda terminates its PhIII trial for arrhythmia drug

    13 Jun 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/incarda-terminates-phiii-trial-of-its-inhaled-atrial-fibrillation-drug/

    Kyle LaHucik ENDPTS
    13 Jun 2023
    Share Share
    InCarda, PhysIQ and Syneos team for phase 3 flecainide study
    InCarda, PhysIQ and Syneos team for phase 3 flecainide study

    31 Aug 2022

    // Joseph Keenan FIERCEBIOTECH

    https://www.fiercebiotech.com/cro/incarda-physiq-and-syneos-team-phase-3-flecainide-study

    Joseph Keenan FIERCEBIOTECH
    31 Aug 2022
    Share Share
    physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health
    physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

    24 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220824005139/en

    BUSINESSWIRE
    24 Aug 2022
    Share Share
    InCarda Therapeutics Provides Corporate Update
    InCarda Therapeutics Provides Corporate Update

    10 Jun 2021

    // BIOSPACE

    https://www.biospace.com/article/-incarda-therapeutics-provides-corporate-update-highlighting-new-phase-2-data-for-inrhythm-program-plans-for-pivotal-phase-3-study-and-expansion-of-senior-management-team/

    BIOSPACE
    10 Jun 2021
    Share Share
    InCarda unrolls mid-stage data backing inhaled arrhythmia drug
    InCarda unrolls mid-stage data backing inhaled arrhythmia drug

    09 Jun 2021

    // Max Gelman ENDPTS

    https://endpts.com/with-its-eyes-set-on-an-ipo-raise-incarda-preps-to-unroll-mid-stage-data-backing-inhaled-arrhythmia-drug/

    Max Gelman ENDPTS
    09 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search